基本信息
浏览量:8
职业迁徙
个人简介
Research Abstract
Lung cancer is the leading cause of death from cancer in the United States. Better understanding of oncogenes and tumor suppressor genes involved in lung cancer hold the promise of improving clinical care of afflicted patients.
Prior work from our group has focused on transcription factors involved in lung cancer and mechanisms of sensitivity/resistance of oncogene kinases (such as EGFR, ALK, ROS1, MET, BRAF, RET, ERBB2, NTRK, KRAS among others) to tyrosine kinase inhibitors in non-small-cell lung cancer.
Our group is also part of the clinical research effort at Dana-Farber/Harvard Cancer Center (DFHCC), with a focus in lung cancer, tumor genomic biomarkers and immune checkpoint inhibitors. We are supported by both federal and non-federal grants, and were part of the previously funded NIH/NCI SPORE in Lung Cancer at DFHCC.
One of the main focuses of the DFHCC Lung Cancer Program, in conjunction with the Cancer Clinical Trials Office (CCTO) at Beth Israel Deaconess Medical Center (BIDMC), is to conduct clinical trials that will establish the future evidence-based strategies to manage local, locally advanced and advanced lung cancers.
研究兴趣
论文共 283 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JTO CLINICAL AND RESEARCH REPORTSno. 1 (2024): 100614-100614
LUNG CANCER (2023): 107423-107423
CANCER DISCOVERYno. 9 (2023): 2107-2107
引用116浏览0引用
116
0
Translational lung cancer researchno. 7 (2023): 1590-1610
Targeted oncologyno. 6 (2023): 807-817
Lung Cancer (2023): 107250-107250
引用0浏览0WOS引用
0
0
Zachary R Schoepflin,Emmeline Academia,Soravis A Osataphan,Deepa Rangachari,Sheida Sharifi,Paul A VanderLaan,Daniel B Costa
JTO clinical and research reportsno. 4 (2023): 100489-100489
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn